Tests aid diagnosis of primary biliary cholangitis
Answers from the Lab
Primary biliary cholangitis, or PBC, is an autoimmune liver disease that can cause liver failure and death. In this test-specific episode of the "Answers From the Lab" podcast, Anne Tebo, Ph.D., Co-Laboratory Director of the Antibody Immunology Laboratory and Professor at DLMP, Mayo Clinic, explains how Mayo Clinic Laboratories' new testing expands the options for diagnosing PBC.
The presence of anti-mitochondrial antibodies or AMA is hallmark feature of PBC. However, a subset of PBC patients are seronegative for AMA and testing for the PBC-specific autoantibodies, anti-Sp100 and anti-gp210 antibodies may be useful in their evaluation. Mayo Clinic Laboratories has launched new ELISA serum tests that identify antibodies to Sp100 and GP210 — two other antibodies associated with PBC — in AMA-negative patients. The tests can be ordered individually (Test IDs: SP100 and GP210) or together in a new PBC panel (Test ID: PBC2).
"Testing for SP100 and GP210 antibodies, in addition to AMA, is recommended for all patients with suspicion for PBC. This is really an appropriate standard of care," Dr. Tebo says.
Mayo Clinic Laboratories' new PBC Antibody Panel (Test ID: PBCPN) evaluates at-risk or previously diagnosed PBC patients with new features of other liver or autoimmune diseases. It covers AMA, Sp100, GP210, and two indirect fluorescent antibodies.
"The comprehensive panel provides an optimal approach, as it has the potential to support the diagnosis of AMA-positive and -negative PBC patients, as well as identify patients with coexisting systemic autoimmune diseases," Dr. Tebo says.
Listen to learn more about Mayo Clinic Laboratories' SP100, PBCPN, PBC2, and GP210 testing.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
SP100 | SP100 Antibody, IgG, Serum
GP210 | GP210 Antibody, IgG, Serum
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.